Transplant medicine in general practice: shared care, surveillance, and safety

Australia has more than 30,000 people living with a functioning solid organ transplant — kidney, liver, heart, lung, pancreas, or a combination — plus an estimated 10,000 haematopoietic stem cell transplant (HSCT) survivors, with approximately 1,000 new HSCT procedures performed each year. For each of these people, the GP is not a passive bystander: shared care between the transplant centre and general practice is the model that AU health guidelines endorse, and in practice it means the GP is the clinician these patients see most often. Preventive care, comorbidity management, vaccination, skin cancer surveillance, medication reconciliation, mental health support, and acute triage all fall within the GP’s scope. This article outlines what general practice needs to know to provide safe, comprehensive care for transplant recipients.

A. Core clinical assessment

History: The essential baseline for every transplant recipient in your panel includes the type of organ transplanted and the date, the transplant centre and lead clinician’s contact details, the current immunosuppressant regimen with drug levels, results from the most recent surveillance bloods, rejection history, infection history, and cancer screening status. Patients should carry a transplant card or pharmacy list; if they do not, encourage them to obtain one from the transplant centre.

Current immunosuppressant regimens typically combine:

• A calcineurin inhibitor — tacrolimus or cyclosporine — whose blood levels are monitored regularly because the therapeutic window is narrow
• An antimetabolite — mycophenolate (MMF) or azathioprine
• A corticosteroid (some centres pursue steroid minimisation or withdrawal after the first year)
• Some patients also take an mTOR inhibitor — sirolimus or everolimus — in place of or alongside the calcineurin inhibitor

Examination: Vital signs including temperature at every visit. Weight and BMI. Targeted cardiovascular examination with blood pressure (target below 130/80 mmHg for most transplant recipients per KDIGO). Graft site palpation — the kidney transplant graft is typically palpable in the right iliac fossa and tenderness there is clinically significant. Comprehensive skin examination — every consultation is an opportunity, though the formal annual full-skin examination should be a dedicated, unhurried encounter. Lymph nodes. Oral mucosa for candidiasis, gingival hyperplasia (cyclosporine), and herpetic ulceration. Neurological screen for tremor, which is common with calcineurin inhibitors.

Surveillance investigations (coordinate timing with the transplant centre):

• FBC — for cytopenias from antimetabolite toxicity, CMV, or the early haematological signal of post-transplant lymphoproliferative disorder (PTLD)
• Renal function (UEC, creatinine, eGFR) — graft function in kidney recipients; calcineurin inhibitor nephrotoxicity in all others
• LFTs — graft function in liver recipients; hepatotoxicity in others
• HbA1c and fasting glucose — new-onset diabetes after transplantation (NODAT) affects 25–40% of solid organ recipients and is driven by tacrolimus, steroids, and pre-existing insulin resistance
• Fasting lipids — dyslipidaemia is almost universal and cardiovascular disease is the leading cause of long-term mortality
• Drug levels — tacrolimus, cyclosporine, sirolimus, or everolimus trough levels per transplant centre protocol; these are not routine pathology items and timing matters
• CMV PCR — viral load surveillance; protocol-directed in the first 6–12 months post-transplant and on clinical indication thereafter
• EBV PCR — at baseline and for PTLD surveillance
• BK polyomavirus PCR — particularly in kidney transplant recipients, in whom BK nephropathy is a significant cause of graft loss

B. Evidence appraisal

Live vaccines post-transplant — absolute contraindication. Case reports and immunological reasoning support this consistently. No trial will ever randomise immunosuppressed transplant recipients to a live vaccine. The ATAGI immunocompromised vaccination guidance is clear: live vaccines (MMR, varicella, Zostavax, BCG, oral typhoid, oral polio, yellow fever) must not be given after transplantation. The risk of vaccine-strain disseminated disease is real; the benefit accrues only by completing live vaccines before transplantation if the schedule allows.

Shingrix (recombinant zoster vaccine) is safe and recommended. The largest evidence base comes from immunocompromised oncology and transplant cohorts. Shingrix does not contain live virus; it cannot cause varicella or zoster. Immunogenicity is reduced compared with immunocompetent individuals but still clinically meaningful. ATAGI now recommends Shingrix for transplant recipients ≥18 years at risk of VZV reactivation, two doses separated by two to six months. This directly replaces the previously used Zostavax in this population.

Annual full-skin examination. Large cohort data confirm non-melanoma skin cancer (NMSC) risk approximately 50 times the general population in kidney transplant recipients, driven by impaired immune surveillance of HPV-transformed keratinocytes. Squamous cell carcinoma in transplant recipients is more aggressive, metastasises more readily, and has higher disease-specific mortality than SCC in immunocompetent individuals. Annual skin examination is standard of care per TSANZ and RACGP consensus; it is not controversial. Daily SPF 50+ sunscreen use reduces NMSC incidence in transplant recipients — one randomised trial (Darlington 2003, NEJM) demonstrated a significant reduction in new keratotic lesions in kidney transplant recipients assigned to daily sunscreen.

CYP3A4 drug interactions — high confidence, high consequence. Tacrolimus and cyclosporine are high-clearance CYP3A4 substrates with steep concentration-effect relationships. Macrolide antibiotics, azole antifungals, diltiazem, and verapamil reliably raise calcineurin inhibitor (CNI) blood levels into the toxic range; rifampicin and St John’s wort reliably drop them into the subtherapeutic range, triggering rejection. These are not theoretical interactions — they are documented in pharmacokinetic studies and transplant centre adverse event registers. The practical rule for GPs is: before prescribing any new medication for a transplant recipient, check eTG or confirm with the transplant pharmacist.

NODAT — aggressive metabolic management warranted. New-onset diabetes after transplantation increases cardiovascular mortality, graft loss, and infection risk. Tacrolimus is more diabetogenic than cyclosporine; corticosteroids amplify the risk. Standard diabetes management principles apply — lifestyle, metformin (where tolerated and eGFR permits), and escalation per RACGP T2DM guidelines — but the transplant centre should be aware of agent selection, particularly with agents that affect renal haemodynamics in kidney transplant recipients.

C. Complications framework

Six categories of post-transplant complications underpin the GP’s clinical reasoning for this population:

1. Rejection — Acute T-cell mediated rejection and acute antibody-mediated rejection typically occur in the first year and present with graft dysfunction. Chronic rejection (chronic allograft dysfunction) is insidious and the principal cause of late graft loss. Fever, graft tenderness, and changes in organ function markers are the GP triggers for same-day transplant centre contact.

2. Opportunistic infection — The timeline matters (see FAQ above). CMV is the most clinically significant — it causes pneumonitis, hepatitis, retinitis, colitis, and encephalitis, and exerts indirect effects on immune function that amplify rejection risk. PJP presents as progressive dyspnoea and hypoxaemia; cotrimoxazole prophylaxis is highly effective. Cryptococcal meningitis, invasive aspergillosis, and Strongyloides hyperinfection are less common but potentially fatal; the GP’s role is to consider these diagnoses in any transplant recipient with a compatible presentation.

3. Drug toxicity — Calcineurin inhibitor nephrotoxicity (chronic interstitial fibrosis and tubular atrophy), neurotoxicity (tremor, headache, leukoencephalopathy), and metabolic effects (hypertension, hyperkalaemia, hyperglycaemia, dyslipidaemia). Mycophenolate causes dose-dependent GI symptoms and cytopenias. The key GP principle: never adjust immunosuppressant doses — all dose modifications go through the transplant centre.

4. Malignancy — PTLD (post-transplant lymphoproliferative disorder) is an EBV-driven lymphoid proliferation ranging from polyclonal reactive hyperplasia to aggressive diffuse large B-cell lymphoma. It presents with constitutional symptoms, lymphadenopathy, extranodal disease, or graft dysfunction. Kaposi sarcoma (HHV-8), HPV-related anal and cervical carcinomas, and Merkel cell carcinoma are all elevated in frequency. Beyond NMSC, transplant recipients have a modestly elevated risk of most solid organ cancers.

5. Cardiovascular disease — The leading cause of death after the first year in all transplant populations. Hypertension, NODAT, dyslipidaemia, pre-existing CKD, and inflammation all converge. Standard cardiovascular risk management applies; blood pressure target below 130/80 mmHg; statin selection matters (pravastatin or rosuvastatin in CNI-treated recipients, not simvastatin with cyclosporine due to myopathy risk).

6. Bone disease — Steroid-induced osteoporosis is common. Pre-transplant hyperparathyroidism (in kidney recipients) and post-transplant hypophosphataemia add complexity. DEXA at baseline and every one to two years; calcium 1,200 mg and vitamin D 1,000–4,000 IU daily; bisphosphonate per fracture risk assessment.

D. Australian health system operations

MBS items for transplant shared care:

• Standard consultation items 23, 36, 44 — Level C or D complexity is typical given the multimorbidity burden
• Chronic Disease Management: GP Management Plan item 721 and Team Care Arrangement item 723 — appropriate for most stable transplant recipients; enables allied health referral including dietitian, exercise physiologist
• Mental health care plan: items 2715/2717 — depression and anxiety are prevalent in transplant recipients
• Telehealth: items 91890/91891
• DEXA: item 12306 for monitoring bone density
• Skin biopsy: item 30196

PBS — immunosuppressants are Section 100 Highly Specialised Drugs. Tacrolimus (Prograf, Advagraf, Envarsus), cyclosporine (Neoral), sirolimus, everolimus, mycophenolate (CellCept, Myfortic), and azathioprine are all Section 100 HSD — authority-required, specialist-initiated, dispensed through approved hospitals or community pharmacies under the HSD program. GPs can supply ongoing prescriptions once the specialist has initiated. Valganciclovir (CMV prophylaxis and treatment) and cotrimoxazole (PJP prophylaxis) are separately PBS-listed with authority criteria. Preferred statins — pravastatin and rosuvastatin — are PBS general benefit items.

NIP vaccination: ATAGI’s immunocompromised schedule provides funded access to inactivated influenza, pneumococcal (Prevenar 20 and PPV23), COVID-19, and Shingrix (recombinant zoster) under the National Immunisation Program for eligible immunocompromised Australians, including transplant recipients.

Aboriginal and Torres Strait Islander considerations: Item 715 health assessment provides a structured opportunity for comprehensive review of vaccination, cancer screening, metabolic and cardiovascular risk, and mental health in First Nations transplant recipients. Coordinate with the local Aboriginal Community Controlled Health Organisation (ACCHO) and the transplant centre. Closing the Gap PBS co-payment applies to immunosuppressants and supporting medications.

Transplant centre referral network: Australia’s major transplant centres include Austin Health (Victorian Liver Transplant Unit), Royal Melbourne Hospital, Westmead Hospital, Royal Prince Alfred Hospital (Sydney), Princess Alexandra Hospital (Brisbane), Royal Adelaide Hospital, and Sir Charles Gairdner Hospital (Perth). Each has a transplant coordinator and pharmacist accessible to GPs by phone; use them.

E. Special populations

Paediatric transplant recipients transitioning to adult care represent a particular GP challenge. The handover from paediatric to adult transplant services often happens in the late teens; GP engagement during this transition reduces the risk of non-adherence, which is the predominant cause of graft loss in young adults. Practical steps: establish rapport before the formal handover, review the full immunosuppressant list, reinforce sun protection habits, and connect with adult transplant services early.

Pregnancy after transplantation is possible and increasingly common, particularly for kidney and liver recipients, but requires specialist co-management from conception. Mycophenolate is teratogenic and must be switched (to azathioprine) at least six weeks before conception. Calcineurin inhibitors are generally continued at adjusted doses. Risks include pre-eclampsia, preterm birth, gestational diabetes, and graft rejection; outcomes are best with pre-conceptional planning through the transplant centre and a maternal-fetal medicine specialist.

Elderly transplant recipients have a higher burden of comorbidity, polypharmacy, and frailty; drug interactions are more consequential and functional decline more rapid after opportunistic infection. Advance care planning discussions are especially appropriate in this group; raising them proactively is within the GP’s scope.

HSCT (bone marrow transplant) recipients have distinct vulnerabilities depending on whether the procedure was autologous or allogeneic. Allogeneic HSCT recipients may develop graft-versus-host disease (GVHD) — chronic GVHD particularly affects the skin, eyes, mouth, lungs (bronchiolitis obliterans), liver, and GI tract and can require ongoing immunosuppression for years. The BMTSANZ coordinates survivorship guidelines for this group; GP shared care principles are broadly the same as for SOT but with additional focus on GVHD surveillance and the specific secondary malignancy risks of prior cytotoxic conditioning.

When to escalate

These presentations in a transplant recipient require same-day transplant centre contact or ED presentation — do not wait for routine review:

• Fever ≥38°C — immunosuppressed patients cannot mount a reliable febrile response; a temperature of 38°C represents a higher effective immune stimulus than in a non-immunosuppressed individual; same-day workup and transplant centre guidance are mandatory
• Graft tenderness or unexplained pain over the transplant site
• Acute rise in creatinine (kidney transplant) or abnormal LFTs (liver transplant)
• Oliguria or dark urine in a kidney transplant recipient
• Dyspnoea or hypoxaemia — CMV pneumonitis and PJP can deteriorate rapidly
• Mental state change or new neurological deficit — CMV encephalitis, cryptococcal meningitis, PTLD, and CNI neurotoxicity all present this way
• New lymphadenopathy plus constitutional symptoms — PTLD until proven otherwise
• Severe diarrhoea — CMV colitis and Clostridioides difficile require transplant-centre guidance on management and immunosuppressant dose
• Any suspected skin malignancy — urgent dermatology in the context of the elevated NMSC risk

What this article is and is not

This article is educational information about the GP’s role in transplant shared care in Australia, drawing on TSANZ, KDIGO, eTG, BMTSANZ, and ATAGI guidance. It describes the evidence base for shared care practice as of October 2026 and is directed at health professionals.

This article does not constitute individual medical advice, does not replace the treating transplant centre’s specific instructions for any individual patient, and does not substitute for a clinical consultation. Immunosuppressant regimens are highly individualised; no dose change or medication alteration should be made outside the transplant centre’s guidance. Drug interactions in this population are complex and potentially life-threatening — always confirm new prescriptions with a transplant pharmacist or eTG.

---

Sources cited

• Transplantation Society of Australia and New Zealand (TSANZ)
• Australian and New Zealand Society of Nephrology
• KDIGO Clinical Practice Guidelines for Kidney Transplant Recipients
• BMT Society Australia and New Zealand (BMTSANZ)
• Therapeutic Guidelines (eTG) — Transplant medicine
• ATAGI — Guidance for immunocompromised individuals
• Transplant Australia
• DonateLife
• HealthDirect — Organ transplant
• PBS — Section 100 Highly Specialised Drugs
• Australian Medicines Handbook (AMH)